Search

ICER Publishes Final Evidence Report and Policy Recommendations on Therapies for Atopic Dermatitis. The Institute for Clinical and Economic Review (ICER) has published its final evidence report and policy recommendations on the atopic dermatitis treatments: abrocitinib [Pfizer], tralokinumab [LEO Pharma], baricitinib[Olumiant; Eli Lilly and Incyte], upadacitinib [Rinvoq; AbbVie], ruxolitinib [Incyte], dupilumab [Dupixen; Regeneron and Sanofi]. [Extracted from the article]

ICER Publishes Evidence Report on Therapies for Atopic Dermatitis Internet Document: 13 Jul 2021. The Institute for Clinical and Economic Review (ICER) has published an evidence report assessing the comparative economic value and clinical effectiveness of therapies for atopic dermatitis. [Extracted from the article]

Discusses research being done on the effectiveness of pimecrolimus in the treatment of atopic dermatitis among patients in the U.S. Reference to studies by several researchers published in the March 2005 issue of the "Journal of the American Academy of Dermatology"; Consequences of concern over the potential adverse effects associated with the use of corticosteroids; Effect of pimecrolimus treatment on patients' quality of life.

The article discusses research being done on the use of partially hydrolysed whey formula and standard cow's milk formula in infants at high-risk of developing atopic dermatitis, which references a study by A. Bhanegaonkar et al. published in the May 2015 issue of the "Journal of Pediatrics."

The article discusses research on the cost benefits of electronic health (e-health) service to patients with atopic dermatitis in the Netherlands, referencing a study by H. van Os-Medendopr and colleagues published in the "British Journal of Dermatology."

The article discusses research being done on tacrolimus. It references a study conducted by C. Taneja and colleagues published in the February 2008 issue of the "Journal of the American Academy of Dermatology." It states that tacrolimus yields better outcomes and lower costs than pimecrolimus among children with moderate-to-severe atopic dermatitis.

The article discusses research being done on the medical and work loss costs associated with atopic dermatitis in the U.S. It references a study by J. Fowler and colleagues, published in the February 2007 issue of the "Journal of the American Academy of Dermatology." The study assessed a claims database between 1998 and 2004. It found that atopic dematitis posts higher medical and pharmacy costs for employers.

The article discusses research being done on the utilization of pimecrolimus 1% cream in patients with atopic dematitis. It references a study by M. De Backer et al published in the February 2007 issue of the "Journal of the American Academy of Dermatology." Findings showed that for a relatively small amount of drug used, the cream leads to a reduced use of topical corticosteroids and improved quality of life.

Discusses a propensity-matched analysis of outcomes and costs of care in health plan members with atopic dermatitis who initiate therapy with pimecrolimus or tacrolimus. Reference to a study by T. Delea et al, published in the March 2006 issue of the "Journal of the American Academy of Dermatology"; Overview of the research findings.

Reports on the issuance of a clinical guidance on the use of topical calcineurin inhibitors in atopic dermatitis by the European Working Group on Atopic Dermatitis, as of January 2005. Benefits of the topical calcineurin inhibitors for the different aspects of atomic dermatitis treatment.

Reports that a U.S. study which found tacrolimus ointment to be potentially cost effective versus high-potency corticosteroids in atopic dermatitis has incited sheer puzzlement according to Ernst Epstein from California. Arguments advanced against the cost effectiveness of tacrolimus; Question raised on the study's physician authors and disclosure statement; Reply of study authors on the puzzlement experienced by Epstein.

Offers information on the guidance issued by the National Institute for Clinical Excellence in Great Britain to the National Health Service in England and Wales, as of September 2004. Recommendations regarding the use of tacrolimus and pimecrolimus for treatment of atopic dermatitis among adults and children; Information included in the guideline published by NICE regarding diagnosis and management of dyspepsia among adults in primary care; Basis of the guideline issued for patients with hypertension in primary care.

Discusses research being done on the morbidity and cost of atopic dermatitis in Australia. Reference to a study by N. Jenner and colleagues, published in the "Australasian Journal of Dermatology"; Classification systems used to determine disease severity; Outcome of the Dermatology Life Quality Index completed by research subjects.